Throughput

Fluofarma's technology keeps your project moving at high speed throughout the R&D process. Our technology platform enables large-scale screening programs, with 2000 wells tested a day and 2500 individual cells analyzed per well.

As shown in the Figure below, the Fluofarma HCS technology substantially boosts the number of compounds that can be analyzed. The more compounds you test, the more you improve your chances of identifying a blockbuster.

Fluofarma (green) vs. Standard (red) drug discovery process:  

Drug Discovery process with High Content Screening

► With Fluofarma, understand a large number of compounds and optimize your decision making.

 

Download Platform.pdf

Breaking news

  • Scientific Publication

    Fluofarma is glad to announce a new scientific publication in the journal Biochimica et Biophysica Acta - Molecular Cell Research.

    Read more [+]

  • IFSCC 2008

    Fluofarma will be attending IFSCC 2008, in Barcelona, from October 6th to 9th.

    Read more [+]

  • INVITOX 2008

    Fluofarma will be attending the INVITOX 2008 meeting, in Stockholm from September 25th to 28th.

    Read more [+]

  • EuroBio 2008

    Fluofarma will be attending EuroBio 2008, in Paris from October 7th to 9th.

    Read more [+]

  • SMi's Cell-Based Assays 2008

    Fluofarma will be attending SMi's Cell-Based Assays conference, in London from November 19th to 20th.

    Read more [+]

  • GDDI Forum 2009

    Fluofarma will be attending Global Discovery & Development Innovation Forum 2009, in London, from March 2nd to 3rd.

    Read more [+]

FOCUS: Anticancer drugs profiling
Fluofarma has developed DCffer® method, a powerful approach to compare and profile your anti-cancer drugs. Read more [+]